1345847-71-3

Usage

Uses

Used in Pharmaceutical Research and Development:
METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE is used as a building block in the synthesis of new drugs and active pharmaceutical ingredients. Its unique structural features, including the cyclopropane ring, fluoro-substituted phenyl group, and carbamoyl functionality, offer opportunities for designing and studying new compounds with possible medicinal properties.
Used in Drug Discovery:
METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE is used in drug discovery to explore its potential biological activity and develop new therapeutic agents. Its structural diversity and unique functional groups make it a promising candidate for the development of innovative pharmaceuticals with improved efficacy and safety profiles.
Used in Medicinal Chemistry:
METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE is used in medicinal chemistry to study its interactions with biological targets and evaluate its potential as a lead compound for drug development. Its unique structural features and functional groups can be further modified and optimized to enhance its pharmacological properties and therapeutic potential.
Used in Chemical Synthesis:
METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE is used as a valuable building block in chemical synthesis, particularly in the preparation of complex organic molecules and pharmaceutical compounds. Its solubility and metabolic stability, contributed by the methyl ester group, make it an attractive intermediate for the synthesis of various biologically active molecules.

Upstream product

• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 371-40-4 4-fluoroaniline 
• 67-56-1 methanol 
• 849217-48-7 ((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 

Downstream Products

• 849217-58-9 N'-(3-fluoro-4-hydroxyphenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 849217-60-3 N-(4-fluorophenyl)-N'-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide 
• 849217-68-1 cabozantinib 
• 1363402-41-8 N'-(3-fluoro-4-(6-methoxy-7-((1-(tetrahydro-2H-pyran-4-ylamino)cyclopropyl)methoxy)quinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1363402-40-7 N'-(4-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-26-1 (S)-N-{2,5-difluoro-4-[2-(2-methoxypropionylamino)pyridin-4-yloxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-22-7 (R)-N-(2,5-difluoro-4-((2-(2-hydroxypropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-20-5 (R)-N-(4-((2-(2-(benzyloxy)propanamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane1,1-dicarboxamide 
• 1345848-18-1 (R)-N-(2,5-difluoro-4-((2-(2-methoxypropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-16-9 N-(4-(2-(cyclobutanecarbonylamino)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 

Relevant academic research and scientific papers

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

The present invention relates to compounds that modulate cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion, by modulating protein kinase enzymatic activity, and compositions thereof, and methods of using such compounds.

Preparation method of broad-spectrum anti-cancer drug kimatinib (by machine translation)

The preparation method is simple, the reaction conditions are mild . the reaction conditions are mild, the intermediate stability is good, the side reaction: is less likely to occur, and the preparation method is very suitable for industrial production: a

Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.

Preparation method of Cabozantinib

The invention belongs to the field of pharmaceutical chemistry, and relates to a preparation method of Cabozantinib. The preparation method comprises following steps: 4-halogenated-6, 7-dimethoxyquinoline is reacted with 4-aminophenol to prepare a compoun

Preparation method of cabozantinib (S)-malate and intermediate thereof

The invention relates to a preparation method of cabozantinib (S)-malate and an intermediate thereof. The method includes: taking 4-chloro-6, 7-dimethoxyquinoline (I) as the starting raw material, andconducting substitution, condensation and salt formatio

PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.

ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES

The present invention relates to processes, process steps and intermediates useful in the asymmetric bisamidation of malonic ester derivatives wherein the new processes, process steps and intermediates are, for example, useful in the preparation of asymme

COMPOUNDS AS C-MET KINASE INHIBITORS

The present invention relates to compounds, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with the inhibition of the protein tyrosine kinase activi

CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES

The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: Formula I or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.